Compare Recursion Pharmaceuticals Inc (RXRX) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while First Trust Cloud Computing ETF trades at $158.17. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SKYY | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | — |
52-Week High | $6.79 | $168.91 |
52-Week Low | $2.84 | $104.16 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SKYY, the First Trust Cloud Computing ETF, trades at $159.62, down 1.2% on the day. Technical indicators show a neutral to bullish bias, with moving averages bullish and oscillators neutral. Recent news highlights strong AI-driven demand for cloud infrastructure, positioning SKYY to benefit from secular trends in cloud migration and data center investments.
The outlook for SKYY is positive, driven by AI adoption and cloud spending growth, but risks include market volatility and sector competition. Analyst sentiment is supportive, with the ETF offering diversified exposure without heavy concentration in mega-cap tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
